TORONTO and WINNIPEG, Jan. 16 /CNW/ - Cangene Corporation today announces that it has been informed by the U.S. government that the original request for proposal (“RFP”) related to a contract for the development and supply of therapeutics to treat neutropenia resulting from acute exposure to ionizing radiation, also known as acute radiation syndrome or “ARS”, has been withdrawn and replaced with a new RFP that was issued today. Cangene had submitted a proposal for developing a treatment for ARS in response to the first RFP during 2008. The new RFP is similar to the original but is focused on a five-year program of research and development activities that will support the progression of new therapies for treating ARS down the path towards product licensure, without a product-supply component. Cangene plans to modify its original proposal and submit the revised version in response to this new RFP.
